Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor

M. Raymond V Finlay*, Mark Anderton, Susan Ashton, Peter Ballard, Paul A. Bethel, Matthew R. Box, Robert H. Bradbury, Simon J. Brown, Sam Butterworth, Andrew Campbell, Christopher Chorley, Nicola Colclough, Darren A E Cross, Gordon S. Currie, Matthew Grist, Lorraine Hassall, George B. Hill, Daniel James, Michael James, Paul KemmittTeresa Klinowska, Gillian Lamont, Scott G. Lamont, Nathaniel Martin, Heather L. McFarland, Martine J. Mellor, Jonathon P. Orme, David Perkins, Paula Perkins, Graham Richmond, Peter Smith, Richard A. Ward, Michael J. Waring, David Whittaker, Stuart Wells, Gail L. Wrigley

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science